Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Update

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 4,820,000 shares, an increase of 8.6% from the December 15th total of 4,440,000 shares. Based on an average daily trading volume, of 400,900 shares, the days-to-cover ratio is currently 12.0 days. Approximately 19.6% of the company’s shares are sold short.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ARCT. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Arcturus Therapeutics by 45.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after purchasing an additional 712,650 shares in the last quarter. Millennium Management LLC boosted its holdings in Arcturus Therapeutics by 250.1% in the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock worth $13,515,000 after acquiring an additional 396,505 shares in the last quarter. Empire Life Investments Inc. purchased a new stake in shares of Arcturus Therapeutics during the third quarter worth about $3,498,000. ARK Investment Management LLC increased its holdings in shares of Arcturus Therapeutics by 6.9% during the third quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock valued at $48,765,000 after acquiring an additional 136,074 shares in the last quarter. Finally, PDT Partners LLC purchased a new position in shares of Arcturus Therapeutics in the 3rd quarter valued at approximately $1,744,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

Shares of NASDAQ:ARCT opened at $16.79 on Friday. The firm has a 50 day moving average of $17.46 and a 200 day moving average of $19.85. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. During the same quarter in the previous year, the firm earned ($0.61) earnings per share. Equities research analysts predict that Arcturus Therapeutics will post -2.31 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.